Online tools and informative Web sites
ASTHMyths
This comprehensive Web site can help your patients separate asthma facts from fiction.
Helpful tools from ASTHMyths:
Symptom diary Asthma Action Plan School/Day Care ChecklistAsthma Emergency Card
This is a helpful resource where you can keep important information.
Free 30-day supply for your patients
Provide your eligible patients with a free 30-day supply of SINGULAIR using this simple, printable eVoucher. Limitations apply. Please see Terms and Conditions for details.
Get the eVoucher now >A.I.R. Program
The Asthma Information Resource Program is an educational program with potential prescription savings aimed at helping your patients' adherence to medication. Not all patients are eligible.
Asthma Therapy Assessment Questionnaire (ATAQ)
The NIH guidelines recommend scientifically validated self-assessment tools like ATAQ to help monitor asthma control.
Visit asthmacontrolcheck.com >The following organizations and Web sites can provide more information about asthma:
- National Asthma Education and Prevention Program
- National Heart, Lung, and Blood Institute
- 301-592-8573
- www.nhlbi.nih.gov
- American Lung Association
- 800-LUNG-USA (800-586-4872)
- lungusa.org
- Asthma and Allergy Foundation of America
- 800-7-ASTHMA (800-727-8462)
- aafa.org
- Allergy and Asthma Network
- Mothers of Asthmatics
- 800-878-4403
- aanma.org
- American Academy of Allergy Asthma & Immunology
- 800-822-2762
- aaaai.org
- American Academy of Pediatrics
- 847-434-4000
- aap.org
- American College of Allergy, Asthma & Immunology
- 800-842-7777
- acaai.org
- MerckSource®
- mercksource.com
MerckSource is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.
For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.
Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB.
SELECTED SAFETY INFORMATION
- SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
- Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
- Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
- Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.
Before prescribing SINGULAIR, please read the Prescribing Information.
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PRIVACY POLICY